ITOS Stock Price, Chart, Stats & News
iTeos Therapeutics, Inc. (ITOS) does not currently pay a dividend.
ITOS chart
Price history is unavailable
We don't have enough price data for ITOS to draw a chart yet.
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -6.25% |
ROA | -32.49% |
ROE | -35.52% |
D/E | 0.01x |
Interest coverage ratio | – |
ITOS valuation
P/E | – |
P/S | – |
P/B | 0.90x |
P/CF | -4.09x |
P/FCF | -4.13x |
P/OCF | -4.09x |
PEG | 0.04x |
EV multiple | -3.33x |
About
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC).
Similar securities
Based on sector and market capitalization
